USA flag logo/image

An Official Website of the United States Government

AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3009
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3009
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
American Biotechnology Co
7658 Standish Pl - Ste 107 Rockville, MD 20855
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.
Agency: HHS
Contract: N/A
Award Amount: $49,593.00
 

Abstract:

AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.THIS PROJECT INVOLVES DETERMINING THE ABILITY OF A NEW CLASS OF SYNTHETIC BIOLOGICAL RESPONSE MODIFIERS (BRM) KNOWN AS METHYLFURYLBUTYROLACTONES (MFBL) TO AUGMENT THE PRODUCTION OF LYMPHOKINES (IL-2, B-CELL GROWTH FACTOR, AND IMMUNE INTERFERON) AND MONOKINES (IL-1, PROSTAGLANDINS, AND CYTOLYTIC FACTOR). OUR LABORATORY HAS DETERMINED THAT THE MFBLS ARE POTENT IMMUNOSTIMULATORY COMPOUNDS. MFBLS ARE CAPABLE OF INCREASING THE FOLLOWING IMMUNE FUNCTIONS: 2.PRIMARY AND SECONDARY ANTIBODY PRODUCTION 3.PHAGOCYTOSIS BY BOTH MACROPHAGES AND PMNS. IT IS KNOWN THAT THE ABOVE MENTIONED IMMUNE FUNCTIONS ARE REGULATED IN SOME WAY BY LYMPHOKINES AND/OR MONOKINES. THEREFORE, WE PLAN TO INVESTIGATE THE POSSIBILITY THAT MFBLS ENHANCE THESE IMMUNE FUNCTIONS BY STIMULATING AN INCREASED PRODUCTION OF LYMPHOKINES AND/OR MONOKINES. THIS HYPOTHESIS WILL BE TESTED BOTH IN VIVO AND IN VITRO USING ESTABLISHED MURINE LYMPHOKINE AND MONOKINE ASSAY SYSTEMS.

Principal Investigator:

Michael w. baseler
PRINCIPAL INVESTIGATOR
3012949553

Business Contact:

Small Business Information at Submission:

American Biotechnology Co., In
7658 Standish Place, Suite 107 Rockville, MD 20855

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No